NGNithya Jaideep Gogtay

Nithya Jaideep Gogtay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nithya Jaideep Gogtay has a total of 140 co-authors. Here are the top co-authors by number of shared publications:

  • Urmila M. Thatte

    Department of Clinical Pharmacology, Seth GS Medical College & KEM Hospital, Parel-400 012, Mumbai, Maharashtra, India

    7 shared publications
  • Kannan Sridharan

    Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama 26671, Bahrain

    5 shared publications
  • Urmila M Thatte

    Seth GS Medical College and KEM Hospital, Mumbai, India

    5 shared publications
  • Renju Ravi

    Department of Clinical Pharmacology, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia

    4 shared publications
  • Debdipta Bose

    Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India

    3 shared publications
  • Debdipta Bose

    Department of Clinical Pharmacology, Seth GS Medical College & KEM Hospital, Parel-400 012, Mumbai, Maharashtra, India

    3 shared publications

Latest Publications

  • Open Access

    Evolution of post-trial access in India: An analysis of ethical and regulatory guidelines

    by Nithya J Gogtay, Vijaya L Chaudhari, Prachi V Bhoir, Nikita S Sawant, Urmila M Thatte

    Background: Post-trial access (PTA) is an important element of any ethics or regulatory guidance document. It was first introduced in the Declaration of Helsinki (DoH) in the year 2000 but has only recently gained momentum. The objective of this narrative review was to examine the evolution of PTA in Indian bioethical and regulatory guidelines. Methods: Websites of all Indian government agencies that issue ethics guidelines periodically as well as the website of the Indian regulator was searched by three authors and the guidelines downloaded. Identification of PTA in the guidelines was done by all authors and a consensus was reached. The Scale for the Assessment of Narrative Review Articles (SANRA) criteria were used as the reference framework. Results: The Indian Council of Medical Research (ICMR) guidelines of 2000 and 2006 mention PTA, though the most comprehensive coverage can be seen in the 2017 ICMR guidelines. This was followed by a good coverage of PTA in the New Drugs and Clinical Trials (NDCT) rules of 2019. Other guidelines have also briefly alluded to PTA. Conclusion: In the years to come, Indian guidelines must evolve beyond PTA towards post-trial provisions (as introduced in DoH, 2024) or post-trial care, which are broader in their vision and go beyond the individual participant in a clinical trial.

  • Open Access

    Status of registration, re-registration, and accreditation of ethics committees with Central Drugs Standard Control Organization, Department of Health Research, and National Accreditation Board for Hospitals and Healthcare Providers – An evaluation of the extent of ethics oversight in the country

    by Ananya Rakshit, Karan Muzumdar, Nithya Jaideep Gogtay, Yashodhan Desai, Urmila Mukund Thatte

    Context: The “New Drugs and Clinical Trials Rules 2019” mandates that Ethics Committees (ECs) register with the Central Drugs Standard Control Organization (CDSCO), while ECs overseeing Postgraduate (PG) theses and academic studies must register with the Department of Health Research (DHR). National Accreditation Board for Hospitals and Healthcare Providers (NABH) accreditation of ECs is currently optional. Aim: To evaluate the current status of EC registration and re-registration with CDSCO, DHR and accreditation of NABH as a metric of ethical oversight. Subjects and Methods: Data from January 1, 2019, to September 30, 2022 were collected from the organizational websites and the National Medical Commission (NMC). Registration and re-registration data for ECs were matched against the volume of studies in the Clinical Trials Registry India (CTRI), the number of ECs per state, and state populations. Descriptive and inferential statistics were applied. Results: Of the 770 ECs registered with CDSCO, 38.3% were reregistered. Of the 977 DHR-registered ECs, only 17% were re-registered. Among 370 NMC-recognized PG medical institutes, 49.72% had DHR-registered ECs. Only 13% (186/1400) ECs were NABH accredited from the overall data. A total of 14,551 regulatory studies were registered with CTRI. Among the major states (>4% of Indian population), Maharashtra had the highest percentage of CDSCO-registered ECs at 20% and accounted for 14% of regulatory studies, while states such as Bihar and West Bengal had lower percentages of both CDSCO registered ECs and regulatory studies. Conclusion: The registration, re-registration status of ECs, and accreditation are not commensurate with the quantum of regulatory and academic studies in the country.


  • Open Access

    Authors’ reply

    by Palvi Kudyar, Dhruve Soni, Nithya Jaideep Gogtay

  • Open Access

    Evaluation of satisfaction and reasons for participation in a Covid-19 vaccine clinical trial: A single-centre, observational study

    by Palvi Kudyar, Dhruve Soni, Nithya J. Gogtay

    Background In May 2020, WHO recognized the role of extensive immunization for interrupting the transmission of the SARS-CoV-2 virus. The development of such vaccines in clinical trials relies upon participants who are expected to be vested in the research process. Assessment of participant factors such as motivation and satisfaction are hence important to gauge perspective and ensure successful conduct and completion of these trials. Methods We administered a validated three-domain questionnaire to and documented the binary categorical responses (yes/no) of participants (after informed consent) who had taken both doses of COVOVAX™ in a phase 3 trial at our institute. Association of the dependent variables (participant responses) with the independent variables (participant demographics and socioeconomic strata) was computed using Chi-square test at 5% significance. In case of a significant association, Bonferroni post-hoc test was applied for multiple comparisons. Results Of the 78 participants who were administered the questionnaire, two-thirds were highly satisfied with their experience at our site. Gaining access to a new vaccine was a primary motivation overall (74%) and also in graduates (p=0.03) and middle-class population (p=0.002), whereas the lower-middle class population (p<0.0001) and those educated till secondary school (p=0.003) took part due to the long wait for government-approved vaccines. Conclusion Participants in a Covid-19 vaccine trial at Mumbai were largely satisfied with the care given to them though altruism did not feature as a primary reason for participation.


  • A Systematic Review and Meta-Analysis of the Safety of Hydroxychloroquine in a Randomized Controlled Trial and Observational Studies

    by Debdipta Bose, Mahanjit Konwar, Miteshkumar Maurya, Urmila M. Thatte, Nithya J. Gogtay

    Introduction: Hydroxychloroquine (HCQ) has recently become the focus of attention in the current COVID-19 pandemic. With an increase in the off-label use of HCQ, concern for the safety of HCQ has been raised. We, therefore, performed this systematic review to analyze the safety data of HCQ against placebo and active treatment in various disease conditions. Methods: We searched PubMed, Embase, and Cochrane for Randomized Controlled trials (RCTs) and Observational studies (OSs) that evaluated HCQ for the treatment of any disease other than COVID19 in adult patients up to May 2020. We assessed the quality of the included studies using Risk of Bias 2 (for RCTs) and Newcastle–Ottawa Scale (for OSs). Data were analyzed with random-effect meta-analysis. Sensitivity and subgroup analyses were performed to identify heterogeneity. Results: A total of 6641 studies were screened, and 49 studies (40 RCTs and 9 OSs) with a total sample size of 35044 patients were included. The use of HCQ was associated with higher risks of TDAEs as compared to placebo/no active treatment [RR 1.47, 95%CI 1.03-2.08]. When HCQ was compared with active treatments, the risks of AEs [RR 0.74, 95% CI 0.63-0.86] and TDAEs were less in the HCQ arm [RR 0.57, 95% CI 0.39-0.81]. The outcomes did not differ in the sensitivity analysis. Conclusion: The results suggest that the use of HCQ was associated with a lower risk of AEs and TDAEs as compared to active treatment, whereas posing higher risk of TDAEs as compared to placebo.

  • Population Pharmacokinetics of Hydroxychloroquine Sulfate in Healthcare Workers, Given for Prophylaxis Against Coronavirus Disease 2019 (COVID‐19) in India

    by Jeffrey Pradeep Raj, Nithya Jaideep Gogtay, Avaneesh Pandey, Ashish Kumar Kakkar, Nusrat Shafiq, Padmaja Mekala, Usharani Pingali, Arun Prasath Raju, Surulivelrajan Mallayasamy, Nilima Arun Kshirsagar

    Healthcare workers (HCWs) and frontline workers were recommended hydroxychloroquine (HCQ) 400 mg twice a day on day 1, followed by 400 mg once weekly for the next 7 weeks, as prophylaxis against COVID‐19. There was limited information on the population pharmacokinetics (popPK) of HCQ in an Indian setting when administered for prophylaxis against COVID‐19, and hence this study was proposed. It was a multicentric prospective study conducted at 3 sites in India wherein HCWs who were already on HCQ prophylaxis, who were about to start prophylaxis or who had stopped the prophylaxis for any reason were enrolled. Each participant gave 2 to 6 blood samples at different time points and whole‐blood HCQ concentrations were assayed using liquid chromatography with tandem mass spectrometry (LC MS/MS). popPK analysis was performed using PUMAS 1.1.0. A total of N = 338 blood samples from N = 121 participants were included in the popPK analysis. A 2‐compartment structural model with linear elimination was able to explain the observed data. Body weight was found to be a significant covariate influencing drug clearance. The final model was assessed using goodness‐of‐fit plots, a visual predictive check and a bootstrap, all of which confirmed that the model was appropriate. Simulations based on the current regimen showed that trough values were below the half‐maximal effective concentration (EC50) of 0.7 μmol against COVID‐19. A new weight‐based dosage regimen was proposed to maintain the trough concentration above the EC50 threshold.


  • Open Access

    Research, residents, and registrars – getting it right

    by Shruti Saha, Nithya Jaideep Gogtay

    Perspect Clin Res, Official publication of Indian Society for Clinical Research,India

  • Open Access

    Placing the results of the SOLIDARITY trial with regards to remdesivir in perspective

    by Debdipta Bose, Nithya Jaideep Gogtay, Sujeet K Rajan

    Remdesivir, a repurposed antiviral, was first accorded approval by the US Food Drug Administration (FDA) for the treatment of COVID-19 which necessitates hospitalization. However, the interim data of SOLIDARITY trial revealed no benefits with remdesivir for COVID-19 patients which led immediate debates in social media and the press about the utility of the drug. Both preclinical and clinical data demonstrated its efficacy in COVID-19. The recently concluded ACTT-1 trial showed its efficacy in reducing the duration of hospital stay which is of utmost importance for a country like India where reduction in bed occupancy can save lives of many and eases the financial burden of patient and government. Our benefit-risk analysis of ACTT-1 trial also favored the use of remdesivir over standard of care. The SOLIDARITY trial was fundamentally different from other clinical trials on remdesivir with respect to its design, adaptive nature, and selection of endpoints. Moreover, the success of antiviral therapy also depends on the timing of initiation and combination with other drugs. Hence we believe that drugs like Remdesivir are very important for countries like India where soft end points such as time to recovery and clinical improvement and early discharge become extremely significant during a pandemic.


  • Evaluation of efficacy and safety of fosfomycin versus nitrofurantoin for the treatment of uncomplicated lower urinary tract infection (UTI) in women – A systematic review and meta-analysis

    by Mahanjit Konwar, Nithya J. Gogtay, Renju Ravi, Urmila M. Thatte, Debdipta Bose

    Urinary tract infections (UTI) are among the most frequent medical conditions requiring outpatient treatment. Single dose oral fosfomycin (300 mg) and the older nitrofurantoin (100 mg for 5 days) have been found to be more effective than other first-line drugs in multiple studies. This systematic review and meta-analysis were carried out with the objective of evaluating their comparative efficacy and safety in the management of uncomplicated UTI. Two authors independently searched PubMed, Cochrane Central, Embase, and Google Scholar till Nov 2020 using MeSH terms and free text. Randomized controlled trials (RCTs) comparing both drugs for efficacy and safety in uncomplicated UTI in adult women were included. The primary outcome measures were microbiological and clinical cure rates. The search resulted in n = 663 studies out of which only four studies (three for treatment of uncomplicated UTI in women and one for asymptomatic bacteriuria in pregnancy) satisfied the selection criteria. No significant differences in clinical, (RR 0.95, 95% CI – 0.81, 1.12) and microbiological cure, (RR 0.96, 95% CI – 0.84, 1.08) were found within 4 weeks of treatment. The incidence of adverse events was found to be more in fosfomycin relative to the nitrofurantoin group (RR 1.05, 95% CI – 0.59, 1.87). Hence, single-dose fosfomycin presents a potentially useful and safe treatment option for the treatment of uncomplicated UTI in women and asymptomatic bacteriuria in pregnancy.


  • An Audit of Interim Analyses of Randomized Controlled Trials (RCTs Published in Three High Impact Factor Medical Journals Over a Seven-year Period (2012-2018)

    by Debdipta Bose, Renju S. Ravi, Nithya J. Gogtay, Urmila M. Thatte, Tanvi Borse

    Background: Interim analysis is an integral component of clinical research and drug development in particular and helps reduce 'time to market' for an intervention or stop further development of unsafe and ineffective interventions. In this audit, we evaluated the extent of use of interim analyses in published RCTs in three leading journals and their impact on regulatory approval. Methodology: RCTs published in JAMA, NUM and Lancet in the year 2012 to 2018 were extracted. Each RCT was scrutinized using the filter term 'Interim'. Both descriptive and inferential statistics were used to analyze the data. The factors (therapeutic areas, nature of interventions, source of funding and phases of trials) associated with Interim analysis and its impact on drug approval were analyzed. Results: The majority of RCTs with interim analysis belonged to oncology (27%) and cardiology (17.2%) and were related to drugs (70%). Majority of the RCTs were in phase 3 (56.3%) and funded exclusively by Pharmaceutical industry (36.2%). A total of 2% and 14% studies led to accelerated approval and normal regulatory approval. The choice of alpha spending function was not mentioned in 44.8% studies and 21% studies used O-Brien Fleming method. A total of 18.5% studies were stopped early. The oncology trials, drug as intervention and Phase 3 trials were associated with the conduct of interim analysis which was associated with significantly higher numbers of accelerated and routine regulatory approvals. Conclusion: Majority of the RCTs with interim analysis were from oncology and most did not report a stopping rule. Interventions that were drugs (rather than devices or surgical procedures). and phase 3 trials (relative to other phases of RCTs). were associated with significantly higher number of interim analyses which was also associated with significantly higher number of regulatory approvals.